November 05, 2015 1:58pm EST
Download as PDF
MIAMI--(BUSINESS WIRE)--
OPKO Health, Inc. (NYSE: OPK), a multinational biopharmaceutical and
diagnostics company, will release operating and financial results for
the three months ended September 30, 2015, after the close of the U.S.
financial markets on Monday, November 9, 2015.
OPKO’s senior management will provide a business update and discuss its
results in greater detail in a conference call and live audio webcast at
4:30 p.m. Eastern time on Monday, November 9, 2015.
The conference call dial-in information is listed below. To access the
webcast, please log on to the OPKO website at www.opko.com
at least 15 minutes prior to the start of the call to ensure adequate
time for any software downloads that may be required.
CONFERENCE CALL & WEBCAST INFORMATION
WHEN: Monday, November 9, 2015, 4:30 p.m. ET
INTERNATIONAL DIAL-IN: (330) 863-3454
For those unable to participate in the conference call or webcast, a
replay will be available beginning November 9, 2015 at 7:30 p.m. ET
until November 15, 2015 at 11:59 p.m. ET. To access the replay, dial
(855) 859-2056 or (404) 537-3406. The replay passcode is: 66021053.
The replay can also be accessed for a period of time on OPKO’s website
at www.opko.com .
About OPKO Health, Inc.
OPKO Health, Inc. is a diversified healthcare company that seeks to
establish industry-leading positions in large, rapidly growing markets.
Our diagnostics business includes Bio-Reference Laboratories, the
nation’s third-largest clinical laboratory with a core genetic testing
business and a 420-person sales force to drive growth and leverage new
products, including the 4Kscore® prostate cancer test and the Claros®1
in-office immunoassay platform. Our pharmaceutical business features
Rayaldee™, a treatment for SHPT in stage 3-4 CKD patients with vitamin D
insufficiency (March 29, 2016 PDUFA date) and VARUBI™ for
chemotherapy-induced nausea and vomiting (oral formulation approved by
FDA and pending launch by partner Tesaro, IV formulation in Phase 3).
Our biologics business includes hGH-CTP, a once-weekly human growth
hormone injection (in Phase 3 and partnered with Pfizer), and a
long-acting Factor VIIa drug for hemophilia (entering Phase 2a). We also
have production and distribution assets worldwide, multiple strategic
investments and an active business development strategy. More
information is available at www.opko.com .
View source version on businesswire.com: http://www.businesswire.com/news/home/20151105006539/en/
OPKO Health, Inc.
Tara Mackay, 305-575-4100
Investor Relations
or
Media
Rooney
& Associates
Terry Rooney, 212-223-0689
or
Marion
Janic, 212-223-4017
or
Investors
LHA
Anne
Marie Fields, 212-838-3777
or
Bruce
Voss, 310-691-7100
Source: OPKO Health, Inc.
Released November 5, 2015
email Email Alerts
location_city Company Profile
contact_page Contacts
rss_feed RSS News Feed
account_tree Sitemap
Apply on OPKO Health (Ireland)’s careers page